Skip to main
ALZN
ALZN logo

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has recently reported positive top-line results from its clinical studies, which bodes well for the progress of its innovative treatments for neurodegenerative diseases and psychiatric disorders. The company's proprietary drug candidates, AL001 and AL002, leverage novel technologies aimed at addressing significant medical needs in Alzheimer's treatment, indicating strong potential for market differentiation. Additionally, the current valuation appears attractive based on a net present value analysis, suggesting substantial upside potential and positioning the company favorably for future growth as it achieves key milestones.

Bears say

Alzamend Neuro reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly exceeds prior estimates of $(0.69), highlighting the company's ongoing financial struggles. Notably, the company faces substantial risks related to liquidity and balance sheet stability, as well as significant uncertainties tied to product candidates achieving safety and efficacy in clinical trials and obtaining necessary regulatory approvals. Additionally, external factors such as competition, macroeconomic conditions, investor sentiment towards biotech stocks, and changing healthcare priorities further compound the challenges facing Alzamend Neuro, contributing to a negative outlook for its stock.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.